Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as a sterile solution for injection for subcutaneous use. It is employed in the management of autoimmune disorders and certain cancers, specifically rheumatoid arthritis, psoriasis, psoriatic arthritis, acute lymphoblastic leukemia, and gestational trophoblastic disease, providing disease‑modifying benefits.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Methotrexate is indicated for several autoimmune and oncologic conditions where it modulates cell proliferation and inflammation.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases scaling. - Psoriatic arthritis: alleviates joint pain while treating skin symptoms. - Acute lymphoblastic leukemia: induces remission by inhibiting rapidly dividing leukemic cells. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methofill may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting. - Oral mucosal ulceration. - Fatigue or mild weakness. - Transient elevation of liver enzymes.

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia. - Severe hepatotoxicity or fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Life‑threatening infections due to immunosuppression.

Use of Methofill requires careful monitoring and specific safety measures.

- Liver monitoring: obtain baseline liver function tests and repeat periodically. - Hematologic monitoring: perform regular complete blood counts to detect marrow suppression. - Renal function: assess creatinine clearance before initiation and during therapy. - Pregnancy contraindication: avoid use in pregnant or planning‑to‑be‑pregnant patients (Category X). - Infection risk: counsel patients to report signs of infection promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of nephrotoxicity and gastrointestinal toxicity. - Other folate antagonists (e.g., trimethoprim): potentiate hematologic toxicity.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may alter methotrexate clearance. - Azathioprine or other immunosuppressants: increase risk of bone marrow suppression. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.